Catalyst Pharmaceuticals (CPRX) Gross Profit (2019 - 2026)

Catalyst Pharmaceuticals (CPRX) has 8 years of Gross Profit data on file, last reported at $134.9 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 9.23% year-over-year to $134.9 million; the trailing twelve-month figure through Mar 2026 stood at $513.1 million (up 11.45% YoY), and the FY2025 full-year result was $501.7 million, up 18.64% from the prior year.
• Gross Profit for Q1 2026 stood at $134.9 million, up from $126.5 million in the prior quarter.
• Across five years, Gross Profit topped out at $134.9 million in Q1 2026 and bottomed at $37.2 million in Q1 2022.
• The 5-year median for Gross Profit is $94.8 million (2023), against an average of $93.3 million.
• The widest annual swing landed in 2023, when Gross Profit surged 102.75%; it then grew 5.29% in 2025.
• A 5-year view of Gross Profit shows it stood at $49.6 million in 2022, then surged by 91.19% to $94.8 million in 2023, then advanced by 26.82% to $120.2 million in 2024, then increased by 5.29% to $126.5 million in 2025, then rose by 6.62% to $134.9 million in 2026.
• The last three Gross Profit figures came in at $134.9 million (Q1 2026), $126.5 million (Q4 2025), and $125.7 million (Q3 2025), per Business Quant data.

Peer Comparison